NCT00047229View on ClinicalTrials.gov

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

January 31, 2009

Study Completion Date

April 30, 2009

Conditions
Liver Cancer
Interventions
BIOLOGICAL

oblimersen sodium

DRUG

doxorubicin hydrochloride

Trial Locations (3)

V5Z 4E6

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00047229 - Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | Biotech Hunter | Biotech Hunter